This story, “Bow Hunt For Caribou,” appeared in the April 1955 issue of Outdoor Life. The guides’ banter suddenly ceased. We had broken over the ridge on the Newfoundland barrens where half an hour ...

Shares of Caribou Biosciences (NASDAQ:CRBU) will be in focus on Friday after the gene-editing biotech announced plans to prioritize its lead oncology clinical programs, CB-010 and CB-011 ...

You can reach Adam on Signal at stataf.54. Caribou Biosciences is delaying the readout of clinical trials involving its CRISPR T-cell therapies for blood cancer — hoping that longer follow-up ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Caribou Biosciences is laying off about a third of its staff and stopping work on an experimental lupus ...

The CAR-NK program, dubbed CB-020, was an induced pluripotent stem cell (iPSC)-derived allogeneic anti-ROR 1 cell therapy aimed at solid tumors. Caribou already revealed in March that it had ...

Caribou Biosciences’ 2025 outlook aimed for key trial readouts for two cancer cell therapies in the first half of the year and the start of clinical testing in an autoimmune disease. The CRISPR ...

Caribou Biosciences is winnowing down for the second time in the last year, dropping a leukemia CAR-T asset and laying off 32% of staff to home in on two lead allogeneic cell therapy candidates.

John Butcher has been at the helm of Caribou Coffee over an eventful seven years. Under his tenure, the Brooklyn Center-based coffee chain launched a new domestic franchising program and underwent ...